secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001558370-23-017058
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences Q3 revenue $160.3M (+37% YoY); GAAP EPS $0.63, non-GAAP $0.97; Board authorizes $200M buyback
--------------------------------------------------------------------------------

- Net product revenue $160.3M (+37% YoY); average WAKIX patients ~5,800 (+350 sequentially).
- GAAP net income $38.5M ($0.63 EPS); non-GAAP adjusted net income $58.8M ($0.97 EPS).
- Board authorized new $200M share repurchase program, replacing $125M prior program.
- Company continues to pursue idiopathic hypersomnia indication; expanded pipeline via Zynerba acquisition (Zygel for Fragile X).
- Repurchased ~1.4M shares for $50M in Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023017058/0001558370-23-017058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023017058/hrmy-20231031x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-017058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer